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Abstract
Background: Homeodomain interacting protein kinase 2 (HIPK2) is an evolutionary conserved serine/threonine kinase
whose activity is fundamental in maintaining wild-type p53 function, thereby controlling the destiny of cells when exposed
to DNA damaging agents. We recently reported an altered conformational state of p53 in tissues from patients with
Alzheimer’s Disease (AD) that led to an impaired and dysfunctional response to stressors.
Methodology/Principal Findings: Here we examined the molecular mechanisms underlying the impairment of p53 activity
in two cellular models, HEK-293 cells overexpressing the amyloid precursor protein and fibroblasts from AD patients,
starting from recent findings showing that p53 conformation may be regulated by HIPK2. We demonstrated that beta-
amyloid 1–40 induces HIPK2 degradation and alters HIPK2 binding activity to DNA, in turn regulating the p53
conformational state and vulnerability to a noxious stimulus. Expression of HIPK2 was analysed by western blot
experiments, whereas HIPK2 DNA binding was examined by chromatin immunoprecipitation analysis. In particular, we
evaluated the recruitment of HIPK2 onto some target promoters, including hypoxia inducible factor-1a and metallothionein
2A.
Conclusions/Significance: These results support the existence of a novel amyloid-based pathogenetic mechanism in AD
potentially leading to the survival of injured dysfunctional cells.
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Introduction
The protein p53 responds to a variety of cellular stresses and
may induce cell cycle arrest or apoptosis In fact, by differential
activation of a large number of target genes and by mitochondrial
functions, p53 is able to sense the intensity of the damage and
modulate biological responses that can range from transient
growth arrest to permanent replicative senescence or apoptosis [1].
The induction of p53 transcriptional activity depends mainly on
posttranslational modifications together with protein/protein
interaction [2]. Another important mechanism that controls p53
function is its conformational stability since p53 is an intrinsically
unstable protein whose structure includes one zinc atom as an
important co-factor for DNA-binding activity in vitro and in vivo
[3,4]. An increased content of an unfolded p53 protein isoform
[5–7] has been reported in numerous tumour cells where p53
harboured different gene point mutations. On the other hand,
conformational changes of p53 towards unfolded isoforms are not
only associated with gene mutations, but post transcriptional
modifications can affect p53 tertiary structure. It is worth noting
that in cellular models of Alzheimer’s Disease (AD), p53 was found
to be conformationally altered, making these cells less vulnerable
to stressors or genotoxic insults [5–7]. When investigating the
mechanism of this alteration, we found that the exposure to
nanomolar concentrations of beta-amyloid (Ab) 1-40 peptide was
responsible for the increased content of unfolded p53 protein [8].
One of the activators that induces p53 posttranslational modifi-
cation and wild-type conformational stability is homeodomain
interacting protein kinase 2 (HIPK2), an evolutionary conserved
serine/threonine kinase able to regulate gene expression by the
phosphorylation of transcription factors and accessory components
of the transcription machinery. HIPK2 is activated in response to
DNA damaging agents or morphogenic signals, thus playing a key
role in differentiation, development or apoptosis [for a review see
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10171refs 9 and 10]. HIPK2 interacts physically and functionally with
p53 and specifically phosphorylates p53 at serine 46 (Ser46) in
response to severe DNA damage, regulating p53-induced
apoptosis [11,12]. In addition, it has recently been shown that
HIPK2 depletion results in p53 protein misfolding, changing the
wild-type conformation to a conformationally altered status with
subsequent abolishment of wild type p53 DNA binding and
transcriptional activity. This can be restored with zinc supple-
mentation [13].
Our purpose was to evaluate whether the altered conforma-
tional state of p53, observed in AD cells, was dependent on an
impaired HIPK2 function and, by the use of two cellular models
of AD, to define whether a deregulation of HIPK2 is involved in
AD pathogenesis. Furthermore, since AD is characterized by an
aberrant metabolism of the amyloid precursor protein (APP), in
turn resulting in an aberrant production of Ab peptides [14], our
intent was to investigate the effect of Ab peptides on HIPK2
expression and DNA-binding activity. The results presented
here may define a hierarchical scale of events related to Ab
activities and eventually lead to a better understanding of AD
pathogenesis.
Results
Ab is responsible for HIPK2 deregulation
We first investigated whether HIPK2 DNA-binding to target
promoters was somehow compromised by nanomolar concentra-
tions of soluble Ab peptides. To this aim, we treated HEK-293
cells with soluble Ab 1-40 at the concentration of 10 nM for 48 h.
As we have previously reported, this enters the cells and induces
conformational changes in p53 protein [5]. Subsequently chro-
matin immunoprecipitation (ChIP) experiments were performed
in order to evaluate the integrity of interaction between HIPK2
and the hypoxia inducible factor-1a (HIF-1a) promoter, as
recently reported [15]. As shown in Figure 1a, HIPK2 binding
to HIF-1a promoter was eliminated by Ab 1-40 treatment,
whereas treatment with the reverse peptide Ab 40-1 failed to do
so. We further evaluated Ab 1-40-induced HIPK2 down-
regulation and mRNA expression was assessed in HEK-293 cells
after treatment with Ab 1-40. As shown in Figure 1b, the analysis
of RT-PCR following normalization to GAPDH expression
revealed that no differences in HIPK2 mRNA expression were
observed when comparing treated to untreated HEK-293 cells.
Figure 1. Ab is responsible for HIPK2 deregulation. (a) ChIP experiments were performed with anti-HIPK2 antibody on HEK-293 cells treated
with 10 nM Ab 1-40 or Ab 40-1 for 48 h. PCR analyses were performed on the immunoprecipitated DNA samples using specific primers for the human
HIF-1a promoter. A sample representing linear amplification of the total input chromatin (Input) was included as control. Additional controls included
immunoprecipitation performed with non-specific immunoglobulins (no Ab). A representative experiment of three independent ones was shown. (b)
HIPK2 mRNA expression was determined in HEK-293 cells, treated with 10 nM Ab 1-40 for 48 h, by reverse-transcriptase (RT)-PCR. GAPDH was used as
loading control. (c) Total cell extracts of HEK-293 cells treated with 10 nM Ab 1-40 for 48 h in the absence or presence of 10 mmol/L MG132 for 6 h
were analysed for HIPK2 expression. Anti-tubulin was used as protein loading control. (d) HEK-293 cells were transfected with HIPK2-Flag and the
degradation-resistant HIPK2-K1182R mutant expression vector. After transfection, cells were trypsinized, replated in triplicate and treated with 10 nM
Ab 1-40 or the reverse peptide Ab 40-1 for 48 h. Total cell extracts were analysed by Western immunoblotting with anti-Flag antibody. Anti-tubulin
was used as protein loading control.
doi:10.1371/journal.pone.0010171.g001
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immunoblotting. As shown in Figure 1c, Ab 1-40 treatment
reduced HIPK2 protein levels in HEK-293 cells, compared to
vehicle or Ab 40-1 treatment. Cell treatment with proteasome
inhibitor MG132 strongly reduced Ab 1-40-dependent HIPK2
down regulation, increasing HIPK2 protein levels to an even
larger extent when compared to control cells (Figure 1c),
suggesting that additional proteasomal degradation processes
besides that induced by Ab 1-40 are likely involved in HIPK2
degradation. Then HEK-293 cells were transfected with HIPK2-
Flag and the degradation-resistant HIPK2-K1182R mutant
expression vectors. Subsequently cells were treated with Ab 1-40
or the reverse inactive Ab 40-1 peptide. As shown in Figure 1d,
HIPK2-Flag expression was down regulated by Ab 1-40 while the
reverse peptide was not effective, as reported above for
endogenous HIPK2 (Figure 1c); Ab 1-40 did not affect the
expression of the K1182 mutant (Figure 1d). Altogether, these
results show that nanomolar concentrations of soluble Ab can
impair HIPK2 binding to DNA, likely through activation of
proteasomal degradation, as assessed by the use of the proteasome
inhibitor MG132.
Endogenous products of APP metabolism negatively
affect HIPK2/DNA binding activity
To acquire more insight into the contribution of the different
APP processing products to HIPK2 deregulation, we used HEK-
293 cells stably transfected with wild type APP751 (HEK-APP)
that express high levels of full length APP in comparison with
HEK-293 cells [5]. In particular, HEK-APP cells produced and
released elevated amounts of Ab peptides (see Table 1), where Ab
1-40 was the more abundant isoform (700 pg/mg protein in
cellular extracts and 200 pg/mL in the conditioned medium after
48 hrs) than Ab 1-42 (78 pg/mg in cellular extracts and 42 pg/
mL in the conditioned medium after 48 hrs). In order to prevent
amyloidogenic APP metabolism, HEK-APP cells were then
treated with b secretase inhibitor (bSI); Ab 1-40 and Ab 1-42
levels were then measured in both cellular extracts and medium
after b secretase inhibition. As shown in Table 1, inhibition of APP
amyloidogenic pathway induced by b secretase inhibitor prevented
the formation of Ab 1-40 and Ab 1-42 in both the cellular extract
and in the medium. HIPK2 binding to HIF-1a promoter was then
evaluated in HEK-293 cells and HEK-APP cells that were also
treated with the bSI. As shown in Figure 2a (left panel), HIPK2
was easily detected in the HIF-1a promoter in HEK-293 control
cells while the recruitment was abolished in HEK-APP cells. Beta-
secretase inhibitor treatment enhanced HIPK2 recruitment onto
HIF-1a promoter (Figure 2a, left panel), strongly suggesting that
APP amyloidogenic metabolites may indeed affect HIPK2 DNA-
binding activity. We then tested the ability of the conditioned
medium of HEK-APP cells to inhibit HIPK2 DNA-binding. To
this aim, HEK-293 cells were cultured with conditioned medium
of HEK-APP cells that, as shown in Figure 2a (right panel),
abolished HIPK2 binding to HIF-1a promoter. In agreement with
our hypothesis, b-secretase inhibitor treatment counteracted the
APP-conditioned medium ability to inhibit HIPK2 binding to
DNA and re-established HIPK2 recruitment onto HIF-1a
promoter (Figure 2a, right panel).
A mechanism through which HIPK2 deregulation may affect
p53 conformation could be through metallothionein 2A (MT2A).
Metallothioneins can act as potent chelators in removing zinc from
p53 in vitro and may modulate p53 transcriptional activity [16]. In
particular, HIPK2 depletion has been observed to induce MT2A
upregulation, whose inhibition by siRNA restored p53 wild-
conformation and transcriptional activity [17]. These findings
suggest that HIPK2 plays a critical role in maintaining p53 wild-
type conformation for DNA binding and transcriptional activity
indirectly through MT2A down regulation. Hence, we investigat-
ed whether HIPK2 activity to bind MT2A target promoter was
somehow compromised in HEK-APP. As shown in Figure 2b (left
panel), ChIP assay showed that the HIPK2 recruitment onto
MT2A promoter was hampered in HEK-APP cells in comparison
with HEK-293 control cells, whereas it was recovered by
treatment with b secretase inhibitor. Furthermore, when HEK-
293 cells were treated with conditioned medium of HEK-APP
cells, we observed an elimination of HIPK2 binding to MT2A
promoter (Figure 2b, right panel). Parallel to data on HIF-1a, b-
secretase inhibitor treatment re-established HIPK2 recruitment
onto MT2A promoter thus counteracting the APP-conditioned
medium ability to affect HIPK2 binding to DNA (Figure 2b, right
panel). These data were supported by the increased HIF-1a-luc
and MT2A-luc activities in HEK-APP cells compared to the
HEK-293 counterparts (Figure 2c). In agreement, MT2A and
HIF-1a mRNA were induced in HEK-APP compared to HEK-
293 cells, although to a different extent (Figure 2d). These data
suggest that impaired HIPK2 binding to DNA in AD cells
correlated with increased HIF-1a and MT2A expression.
p53 transcriptional activity is restored by zinc
Following the data on MT2A overexpression, we wanted to
evaluate whether the p53 dysfunction, related to Ab exposure in
our experimental models, could be restored by zinc supplemen-
tation. Thus, p53 transcriptional activity was evaluated by
luciferase assay of the p53AIP1-luc apoptotic promoter [18].
HEK-APP cells and the control counterparts were transiently
transfected with the p53AIP1-luc reporter plasmid and 24 hrs later
treated with 3.4 mM doxorubicin, a cytotoxic agent able to induce
DNA damage and apoptosis in a p53-dependent manner [19]. As
shown in Figure 3a, p53AIP1-luciferase activity was induced by
doxorubicin treatment in HEK-293 cells, whereas it was
significantly impaired in HEK-APP cells. Zinc supplementation
to HEK-APP cells restored endogenous p53 ability to activate
p53AIP1-luciferase reporter in response to doxorubicin (Figure 3a),
while it only slightly increased p53 transcriptional activity in HEK-
293 cells. Next, analysis of mRNA showed that the doxorubicin-
induced p53 apoptotic gene transcription (i.e., Bax gene) in HEK-
293 cells was impaired after stable transfection of APP751 (HEK-
APP) (Figure 3b, compare lane 4 vs lane 2). In agreement with our
hypothesis, zinc supplementation to HEK-APP cells restored drug-
induced Bax transcription (Figure 3b, compare lane 4 vs lane 5).
Finally, Western immunoblotting showed doxorubicin-induced
Table 1. Levels of Ab 1-40 and Ab 1-42 after treatment with b
secretase inhibitor.
Cell extracts (pg/mg protein) Medium (pg/ml)
Ab 1-40 levels 70066.28 20069.12
Ab 1-42 levels 7865.18 4265.21
Ab 1-40 levels after bSI 48063.17* 12864.32*
Ab 1-42 levels after bSI 4262.12
# 2861.15
#
Levels of Ab 1-40 and Ab 1-42 peptides were measured with a commercial
ELISA kit in the cellular extracts and conditioned media of HEK-APP cells
untreated or treated with b secretase inhibitor at 1 mmol/L for 48 hours. Results
are representative of at least three independent experiments 6 S.E.M.
*p ,0.001 bSI treatment vs corresponding control.
# p,0.01 bSI treatment vs corresponding control.
doi:10.1371/journal.pone.0010171.t001
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(Figure 3c). These data suggest that the Ab-inhibited wild-type 53
apoptotic transcriptional activity, in response to drug, was
reactivated by zinc.
AD fibroblasts show conformationally altered p53
protein and a reduced HIPK2 DNA-binding activity that
are restored by zinc
The conformational status of p53 was analyzed in fibroblasts
derived from AD and non-AD subjects by immunoprecipitation
technique using two conformational-specific antibodies, PAb1620
and PAb240, which discriminate folded versus unfolded p53
tertiary structure [16]. Fibroblasts from AD patients from our cell
repository express high levels of unfolded p53, as shown by Uberti
et al. [7] and replicated in the two representative cell lines used in
the current experimental setting (Figure 4a). Zinc supplementation
to AD fibroblasts strongly reduced p53 mutant-like conformation
(Figure 4a, upper panel), as is also shown by quantitative analysis
of p53 immunoprecipitates (Figure 4a, lower panel). Analysis of
mRNA showed that MT2A expression was upregulated in AD
cells (Figure 4b), suggesting that HIPK2 deregulation might be
involved in p53 misfolding in AD cells, likely through MT2A
upregulation, as previously shown [17]. As on HEK-APP cells, we
then investigated whether HIPK2 activity to bind target promoters
was somehow compromised in AD fibroblasts. As shown in
Figure 4c, ChIP assay showed that the HIPK2 recruitment onto
HIF-1a promoter was present in fibroblasts from control subjects,
whereas it was hampered in AD cells. Of note, zinc treatment to
AD fibroblasts restored HIPK2 binding activity to DNA, likely
counteracting the proteasomal degradation, as previously reported
[20] and thus suggesting that zinc was able to affect the dual role of
HIPK2 as DNA co-repressor and as p53 activator.
Discussion
For the first time, we can describe a link between Ab, AD-
related conformationally altered p53 and HIPK2, a transcriptional
co-repressor and activator of p53 apoptotic function. We
previously demonstrated the existence of an unfolded state of
p53 protein in fibroblasts from AD patients that led to an impaired
and dysfunctional response to stressor [6,21]. Here we examined
the molecular mechanisms underlying the impairment of p53
activity in two cellular models, HEK-293 cells overexpressing the
amyloid precursor protein and fibroblasts from AD patients,
starting from recent findings showing that p53 conformation may
be regulated by HIPK2 [13]. Our data suggest that Ab peptides
may be responsible for HIPK2 deregulation. This is supported by
the observation that Ab peptides down-regulated HIPK2 expres-
sion via proteasomal degradation (Figure 1c and 1d) leading to
HIPK2 disappearance from target promoters such as HIF-1a and
MT2A (Figure 1a, 2a and 2b). In agreement, HIF-1a and MT2A
mRNA upregulation was found in HEK-APP cells that overex-
press APP751 (Figure 2d). The induction of MT2A, depending on
Figure 2. Endogenous products of APP metabolism negatively affect HIPK2 DNA-binding activity. (a) ChIP experiments were performed
with anti-HIPK2 antibody on HEK-293 and HEK-APP cells that were also treated with b-secretase inhibitor at 1 mmol/L for 48 h and on HEK-293 treated
with conditioned medium from HEK-APP cells for 48 h in the absence or presence of b-secretase inhibitor; PCR analyses were performed on the
immunoprecipitated DNA samples using specific primers for the human HIF-1a promoter as shown in Figure 1. (b) ChIP experiments were performed
with anti-HIPK2 antibody on HEK-293 and HEK-APP cells that were also treated with b-secretase inhibitor at 1 mmol/L for 4 8h and on HEK-293 treated
with conditioned medium from HEK-APP cells for 48 h in the absence or presence of b-secretase inhibitor; PCR analyses were performed on the
immunoprecipitated DNA samples using specific primers for the MT2A promoter. (c) HEK-293 and HEK-APP cells were transfected with MT2A-luc and
HIF-1a-luc reporter construct and luciferase activity was measured 36 h after transfection. Results normalized to b-galactosidase activity are
presented as fold of induction of luciferase activity 6S.D. At least three independent experiments performed in duplicate. * p,0.01 (Student t-test).
(d) MT2A and HIF-1a mRNA expression was determined in HEK-APP compared to HEK-293 cells by reverse-transcriptase (RT)-PCR. GAPDH was used as
loading control.
doi:10.1371/journal.pone.0010171.g002
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misfolding and inhibition of p53 transcriptional activity [16];
therefore, the present data suggest that HIPK2 deregulation
in HEK-APP cells and fibroblasts from AD patients might
be involved in p53 misfolding, most likely through MT2A
upregulation.
Attempting to better investigate the contribution of APP
metabolic products in the modulation of HIPK2 expression and
change in p53 conformational state, we then used HEK cells with
wild-type APP able to generate high levels of Ab 1-40 and Ab 1-42
both intracellularly and secreted in the medium, with Ab 1-40
about 10 times more abundant than Ab 1-42 [5]. We found that
reducing APP amyloidogenic metabolism by treating HEK-APP
cells with a b-secretase inhibitor prevented the deregulation of
HIPK2 (Figure 2a, 2b) and likely the generation of the unfolded
p53 isoform. Interestingly, we previously demonstrated that a-
secretase inhibitor did not affect unfolded p53 isoform and did not
modify the cellular response to doxorubicin [5]. It is worthy to
note that the conditioned medium of HEK-APP cells was able to
affect HEK-293 cells recapitulating the HEK-APP phenotype, at
least in terms of HIPK2 DNA-binding and altered p53
conformational changes. The Ab peptides released in the media
by HEK-APP appeared to trigger such effects. In fact, the
conditioned media of HEK-APP cells pretreated with b secretase
inhibitor, were unable to inhibit HIPK2 binding to HIF-1a and
MT2A promoters, in HEK-293 cells (Figure 2b).
HIPK2 has been shown to be down-regulated during hypoxia
by Siah2-induced proteasomal degradation [22]. Moreover,
HIPK2 impairment during hypoxia induces de-repression of
target genes such as HIF-1a, and inhibition of p53 activity [20].
Zinc supplementation to hypoxia-treated cells restores HIPK2
stability and binding to HIF-1a promoter, rescuing also the p53
apoptotic transcriptional activity [20]. Therefore, discovering the
mechanisms of HIPK2 inhibition and the ways to manipulate
HIPK2 activity is an interesting option to affect several biological
pathways [23]. Here we showed a novel mechanism of HIPK2
down-regulation mediated by Ab, likely through activation of
proteasomal degradation. HIPK2 is an unstable protein that is
degraded via the proteasome pathway induced by several E3
protein ligases [24], although the molecular mechanisms under-
lying HIPK2 proteasomal degradation in conditions related to Ab-
exposure deserve further studies.
The deregulation of HIPK2 function was further confirmed in
fibroblasts from sporadic AD subjects, an extra-neuronal model
showing a number of abnormalities in metabolic and biochemical
processes, with some of them mirroring events that occur in the
AD brain [25]. We found that fibroblasts from AD patients are
characterized by a decreased HIPK2 DNA-binding activity,
besides showing a conformationally altered p53. Since one of the
features that distinguishes AD from non-AD fibroblasts is a
defective non-amyloidogenic APP processing, likely favouring an
aberrant Ab peptides production [26], these data suggest that this
abnormality may be, at least in part, responsible for altered
HIPK2 binding to promoters. HIPK2 is ubiquitously expressed
and has been found in developing neurons [27]. HIPK2
overexpression suppresses Brn3a-dependent transcription of brn3a,
trkA and bcl-xL resulting in apoptotic cell death in cultured sensory
neurons [27,28]. Moreover, HIPK2 is an important component in
the TGFb signalling pathway that regulates the survival of
midbrain dopamine neurons, as suggested by HIPK2 knock-out
mice [28,29]. Interestingly, it has been recently shown that HIPK2
is required for the trakA to p75
NTR transition that leads to
increased generation of Ab that accompanies aging [30],
suggesting a regulatory loop that tends to inhibit HIPK2 during
aging contributing to AD.
The impairment of HIPK2 function, by shifting p53 protein
structure from a wild-type to a conformationally altered
phenotype, should increase the threshold to a noxious stimulus,
Figure 3. Zinc supplementation to HEK-APP restores p53 pro-apoptotic transcriptional activity. (a) HEK-293 and HEK-APP cells were
transfected with p53AIP1-luc reporter construct and 24 h after transfection treated with doxorubicin (3.4 mM) and zinc (100 mM) for 24 h before
luciferase activity was assayed. Results normalized to b-galactosidase activity are shown as relative luciferase activity 6S.D. At least three independent
experiments performed in duplicate. * p,0.05 vs HEK-293 or HEK-APP; ** p,0.01 vs HEK-APP (Bonferroni Multiple Comparison test). (b) Bax mRNA
expression was determined in HEK-APP compared to HEK-293 cells by reverse-transcriptase (RT)-PCR after treatment with doxorubicin (3.4 mM) and
zinc (100 mM) for 24 h. GAPDH was used as loading control. (c) Total cell extracts of HEK-APP cells treated with doxorubicin (3.4 mM) and zinc
(100 mM) for 24 h were analysed for Bax and p53 expression. Protein loading control was shown as Ponceau staining.
doi:10.1371/journal.pone.0010171.g003
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the reduced efficacy of doxorubicin-induced apoptosis was due to
an impairment of p53 apoptotic activity. In agreement with our
hypothesis, we found that these cells showed a reduced HIPK2
DNA binding activity and Bax transcription in response to
doxorubicin that was rescued by zinc (Figure 3). Zinc has been
reported to restore p53 function in HIPK2 depleted cells [13,17].
The capability of zinc to act in cells is ascribed to the existence of
zinc transporters, that are required to convey this ion across
cellular membranes, since zinc is unable to passively diffuse across
cell membranes [31]. The use of zinc for AD treatment is
controversial, since several recent works reported the capability of
zinc to cause the precipitation of Ab into nonfibrillar amorphous
aggregates [32]. However, in our experiments we speculate that
the capability of zinc supplementation to restore the Ab 1-40-
inhibited HIPK2 DNA-binding appears not to be associated to a
metal ion-induced precipitation of the synthetic peptide but rather
to counteracting a degradation mechanism. This is supported by
the observations in fibroblasts from AD patients, in which zinc
treatment was able to rescue HIPK2 binding to its target
promoters. However, we could also not exclude the hypothesis
that zinc may be able to withdraw the synthetic peptide from
cellular environment thus modulating its interaction.
In summary, we hypothesize that low amounts of soluble Ab,
not resulting in cellular toxicity, may be responsible for important
modulatory effects at cellular level before triggering the amyloido-
genic cascade. For the first time we found that one of these
modulatory effects may be the inhibition of HIPK2 activity, with
MT2A upregulation, in turn responsible for the induction of an
altered conformational state of p53. As a result of this
conformational change, p53 lost its transcriptional activity and
was unable to properly activate an apoptotic program when cells
were exposed to a noxious stimulus. Altogether, Ab-induced
HIPK2 depletion and unfolded p53 may contribute to AD
pathogenesis leading to dysfunctional cells. The definition of this
new target is useful to help characterize the hierarchical scale of
events driven by beta-amyloid so as to better understand the
pathogenesis of AD. Furthermore, the recognition of HIPK2 as
new target of the effect of Ab could suggest a new putative
functional biomarker useful in addressing new therapeutic
strategies.
Materials and Methods
Reagents and cell treatments
All culture media, supplements and Foetal Bovine Serum (FBS)
were obtained from Euroclone (Life Science Division, Milan,
Italy). Electrophoresis reagents were obtained from Bio-Rad
(Hercules, CA, USA). All other reagents were of the highest
grade available and were purchased from Sigma Chemical Co. (St.
Louis, MO, USA) unless otherwise indicated. Amyloid-b (Ab)
peptide 1-40 and Ab 40-1 reverse peptide were solubilised in
Figure 4. Fibroblasts from Alzheimer patients show misfolded p53 with increased MT2A expression and reduced HIPK2 binding to
DNA. (a, upper panel) Equal amounts of total cell extracts from fibroblasts derived from AD patients were treated with 100 mM zinc for 16 h and
then immunoprecipitated with anti-p53 conformational antibodies, PAb1620 for wild-type conformation and Pab240 for mutant-like conformation.
Immunoprecipitates were analysed by Western immunoblotting with the polyclonal anti-p53 antibody. A representative experiment of three
independent ones was shown. (a, lower panel) Densitometric analysis of immunoprecipitated p53 as above, showing reduction of PAb240 mutant-
like conformation after zinc treatment. *** p,0.0001 vs AD (Student t-test). (b) MT2A expression was determined in fibroblasts derived from AD
patients compared to non-AD patients by reverse-transcriptase (RT)-PCR. GAPDH was used as loading control. (c) ChIP experiments were performed
with anti-HIPK2 antibody on fibroblasts from AD and non-AD patients. PCR analyses were performed on the immunoprecipitated DNA samples using
specific primers for the human HIF-1a promoter. A sample representing linear amplification of the total input chromatin (Input) was included as
control. Additional controls included immunoprecipitation performed with non-specific immunoglobulins (no Ab). A representative experiment of
three independent experiments was shown. Amplification of GAPDH promoter was used as control of HIPK2 binding specificity to the HIF-1a
promoter.
doi:10.1371/journal.pone.0010171.g004
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aliquots that were diluted at the final concentration of 10 nM prior
to use. For each experimental setting, one aliquot of the stock was
thawed out and diluted at the final concentration of 10 nM to
minimize peptide damage due to repeated freeze and thaw. The
Ab concentration was chosen following dose response experiments
(data not shown) where maximal modulation of p53 structure and
its transcriptional activity [5] was obtained at 10 nM. All the
experiments performed with Ab were made in 1% of serum.
Doxorubicin was solubilised in H2O at the concentration of
10 mM and frozen in stock aliquots that were diluted to working
concentration (3.4 mmol/L) in medium at the moment of use. Zinc
Chloride (ZnCl2) was diluted into the cell medium at 100 mM
concentration for 16 h. To test proteasome activity, 6 hours before
the end of treatment MG132 (Calbiochem, San Diego, CA, USA)
was added to the medium at the concentration of 10 mmol/L.
Cell cultures
Skin Fibroblasts from two non-AD controls (2 females, mean
age 63.569.2 years) and two AD patients (1 female, 1 male, mean
age 66.0611.3 years) were selected from the cell lines present in
our cell repository originally established in 1993 [33]. The
diagnosis of probable AD was made according to the criteria
developed by National Institute of Neurological and Communi-
cative Disorders and Stroke (NINCDS) and the Alzheimer’s
Disease and Related Disorders Association (ADRDA). All AD
patients presented a 1–4 year history of progressive cognitive
impairment predominantly affecting memory. Non-AD patients
were without established cognitive disorders. Neither AD nor non-
AD patients presented neoplastic diseases at the time of tissue
biopsy. All cell lines were frozen at passage 2–4 in a modified
growth medium containing 20% foetal bovine serum and 10%
dimethylsulfoxide. For the experiments, cell lines were simulta-
neously thawed and grown up to passages 7–10. Cells were
cultured as previously described [21]. Each set of experiments was
done using cells at the same passage (ranging from 7 to 10),
carefully matching AD and non-AD samples. Culture conditions
were kept constant throughout the experiments.
Human embryonic kidney (HEK) 293 cells from European
Collection of Cell Cultures (ECACC No. 85120602) were cultured
in Eagle’s minimum essential medium containing 10% foetal
bovine serum, glutamine (2 mM), penicillin/streptomycin (2 mM),
at 37uC in 5%CO2/95% air [5]. The HEK-293 cells stably
transfected with APP751 were obtained as previously described [5]
and maintained in G418 at a final concentration of 400 mg/ml.
Transfection, plasmids and Western immunoblotting
Transient transfection was carried out using the N,N-bis-(2-
hydroxyethyl)-2-amino-ethanesulphonic acid-buffered saline (BBS)
version of the calcium phosphate procedure and the following
plasmids were used: HIPK2-Flag [11] and HIPK2-K1182R
(MDM2-resistant) mutant [34]. Total cell extracts were prepared
as previously described [20] and immunoblotting was performed
with mouse monoclonal anti-Flag (Sigma Chemical Co., St. Louis,
MO, USA) and mouse monoclonal anti-tubulin (Immunological
Sciences, Rome, Italy). Immunoreactivity was detected by
enhanced chemiluminescence kit (Amersham, Little Chalfont,
UK).
p53 conformational immunoprecipitation
p53 conformational state was analyzed by immunoprecipitation
as detailed previously [7]. Briefly, cells were lysed in immunopre-
cipitation buffer (10 mM Tris, pH 7.6; 140 mM NaCl; and 0.5%
NP40 including protease inhibitors); 100 mg of total cell extracts
were used for immunoprecipitation experiments performed in a
volume of 500 ml with 1 mg of the conformation-specific antibodies
PAb1620 (wild-type specific) or PAb240 (mutant specific) (Neo-
markers, CA, USA). Immunocomplexes were separated by 10%
SDS-PAGE and immunoblotting was performed with rabbit anti-
p53 antibody (FL393) (Santa Cruz, CA, USA). Immunoreactivity
was detected with the ECL-chemiluminescence reaction kit
(Amersham, Little Chalfont, UK).
RNA extraction and reverse transcription-PCR (RT-PCR)
Total RNA was extracted with TRIzol (Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s instructions. The first
strand cDNA was synthesized by reverse-transcribing 5 mgo f
mRNA with Moloney murine leukaemia virus reverse transcrip-
tase kit and random primers (Applied Biosystems, Foster City, CA,
USA). Semiquantitative RT-PCR was carried out by using Hot-
Master Taq (Eppendorf, Milan, Italy) with 2 ml cDNA reaction
and genes specific oligonucleotides under conditions of linear
amplification. DNA products were run on 2% agarose gel and
visualized by ethidium bromide staining using UV light. Data
presented are representative of at least three independent
experiments.
Chromatin immunoprecipitation (ChIP) analysis
Chromatin immunoprecipitation (ChIP) analysis was carried
out essentially as described [13]. Protein complexes were cross-
linked to DNA in living cells by adding formaldehyde directly to
the cell culture medium at 1% final concentration. Chromatin
extracts containing DNA fragments with an average size of 500 bp
were incubated overnight at 4uC with milk shaking using
polyclonal anti-HIPK2 antibody (Santa Cruz, CA, USA). DNA-
protein complexes were recovered with protein G Agarose (Pierce,
Rockford, IL, USA). Before use, protein G was blocked with 1 mg/
ml sheared herring sperm DNA and 1 mg/ml bovine serum
albumin (BSA) overnight at 4uC and then incubated with
chromatin and antibodies for 3 hrs at 4uC. PCR was performed
using immunoprecipitated DNA and specific primers for human
HIF1a and MT2A promoters [15,17]. Immunoprecipitation with
non-specific immunoglobulins (No Ab) was performed as negative
controls. PCR products were run on a 2% agarose gel and
visualized with ethidium bromide staining using UV light. The
amount of precipitated chromatin measured in each PCR was
normalized with the amount of chromatin present in the input of
each immunoprecipitation.
Transactivation assay
For transactivation assay HEK-293 and HEK-APP cells were
transfected with the p53-target promoter AIP1-luciferase reporter
plasmid (kindly provided by H. Arakawa, National Cancer Center,
Tokyo, Japan), MT2A-luc (kindly provided by Jean-Mark
Vanacker, UMR5242 CNRS/INRA/Universite ´ Claude Bernard
Lyon/ENS, Lyon, France) or HIF-1a-p800-luc (kindly provided
by Carine Michiels, Laboratory of Biochemistry and Cellular
Biology, FUNDP-University of Namur, Belgium) reporter plas-
mids, by using the cationic polymer transfection reagent jetPEI
(PolyPlus-transfection, Illkirch, France) according to the manufac-
turer’s instructions. Twenty-four hours later the cells were
incubated with 100 mM Zinc Chloride (ZnCl2) for 16 h and with
3.4 mM doxorubicin for 24 h before luciferase activity was
assayed. Transfection efficiency was normalized with the use of
a co-transfected pCMV b-galactosidase plasmid (b-gal). Luciferase
activity was assayed on whole cell extract and the luciferase values
were normalized to b-gal activity and protein content. At least
three independent experiments were performed in duplicate.
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All the experiments, unless specified, were performed at least
three times.
Following acquisition of the Western blot image through an
AGFA scanner and analysis by means of the Image 1.47 program
(Wayne Rasband, NIH, Research Services Branch, NIMH,
Bethesda, MD, USA), the relative densities of the bands were
analyzed as described previously [35]. The data were analyzed by
analysis of variance (ANOVA) followed when significant by an
appropriate post hoc comparison test as indicated in figure legend.
The reported data are expressed as means 6 SD of at least three
independent experiments. A p value,0.05 was considered
statistically significant.
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